Growth Metrics

Emergent BioSolutions (EBS) Income from Continuing Operations: 2010-2025

Historic Income from Continuing Operations for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $51.2 million.

  • Emergent BioSolutions' Income from Continuing Operations fell 55.40% to $51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.9 million, marking a year-over-year increase of 136.35%. This contributed to the annual value of -$190.6 million for FY2024, which is 74.94% up from last year.
  • Emergent BioSolutions' Income from Continuing Operations amounted to $51.2 million in Q3 2025, which was up 526.67% from -$12.0 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Income from Continuing Operations high stood at $177.9 million for Q4 2021, and its period low was -$283.1 million during Q2 2024.
  • For the 3-year period, Emergent BioSolutions' Income from Continuing Operations averaged around -$76.7 million, with its median value being -$31.3 million (2024).
  • As far as peak fluctuations go, Emergent BioSolutions' Income from Continuing Operations surged by 657.60% in 2021, and later slumped by 4,932.43% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Income from Continuing Operations (Quarterly) stood at $177.9 million in 2021, then crashed by 137.66% to -$67.0 million in 2022, then grew by 26.12% to -$49.5 million in 2023, then soared by 36.77% to -$31.3 million in 2024, then tumbled by 55.40% to $51.2 million in 2025.
  • Its last three reported values are $51.2 million in Q3 2025, -$12.0 million for Q2 2025, and $68.0 million during Q1 2025.